Indeed, a very recent meta-analysis exclusively for patients with heart failure, including 11 randomized control trials (10,796 patients received SGLT2 inhibitors and 10,796 patients received placebo), demonstrated that treatment with SGLT2 inhibitor was associated with a significant reduction in the risk of SCD (risk ratio: 0.68; 95% confidence interval: 0.48–0.95) (48). This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.